|

Depression Clinical Trials in Connecticut

29 recruiting studies across 11 cities

All Trials in Connecticut

Phase
Trial Phase Location
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)Phase 2Cromwell
Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderPhase 2Cromwell
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Phase 3Cromwell
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Phase 3Cromwell
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)Phase 2Cromwell
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy—Darien
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsPhase 3Farmington
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPhase 3Farmington
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderPhase 2Farmington
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services—Hartford
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence StudyPhase 3Milford
The OBSERVE Protocol—Milford
A Study of Brenipatide in Adult Participants With Major Depressive DisorderPhase 3New Haven
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPhase 3New Haven
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Phase 3New Haven
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine ResponsePhase 1New Haven
Assessing the Effectiveness of Digital Wellness Modules on Perceived Quality of LifeN/ANew Haven
Imaging Depression in Parkinson's DiseasePhase 2New Haven
Open-Label Psilocybin Study in Transdiagnostic PopulationPhase 1New Haven
Stress and Pain in People Living With HIVN/ANew Haven
The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseasePhase 2New Haven
Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum DisorderN/ANew Haven
Study of ALTO-300 in MDDPhase 2Norwalk
Heat and Mental Health - PART 2N/AOrange
E-Mindfulness Approaches for Living After Breast CancerPhase 3Stamford
Healing Hearts: A Mindfulness App for Parents Navigating Divorce or SeparationN/AStamford
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in HumansPhase 1West Haven
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsPhase 2West Haven
ALTO-207 in Adults With Treatment-resistant Depression (TRD)Phase 2Wilton

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.